Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Website: pfizer.com


  • Bad financial results growth rate -32.3% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (5.1%)
  • Dividend yield for the last twelve months 5.6%
  • Free cash flow yield 0.0% (LTM)
  • Share price is 17.9% higher than minimum and 51.4% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (185.6x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $0.1 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: PFE
Share price, USD:  (+1.7%)29.775
year average price 28.80  


year start price 33.64 2023-09-18

max close price 33.99 2023-09-19

min close price 25.26 2024-04-25

current price 29.27 2024-09-16
Common stocks: 5 615 000 000

Dividend Yield:  5.6%
EV / LTM EBITDA: 185.6x
EV / EBITDA annualized: 38.3x
Last revenue growth (y/y):  +4.3%
Last growth of EBITDA (y/y):  -68.9%
Historical revenue growth:  +11.7%
Historical growth of EBITDA:  -1.5%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 167 187
Net Debt ($m): 0
EV (Enterprise Value): 167 187
EBITDA LTM ($m): 901
EV / LTM EBITDA: 185.6x
Price to Book: 1.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-09-16investopedia.com

Pfizer Drug Treating Fatal Weight Loss in Cancer Patients Found Effective

2024-09-15fool.com

Is Pfizer's 5.7% Dividend Yield Worth the Risk?

2024-09-14cnbc.com

Pfizer says its experimental drug for deadly condition that causes appetite and weight loss in cancer patients shows positive trial results

2024-09-14businesswire.com

Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia

2024-09-14reuters.com

Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi

2024-09-13forbes.com

Pfizer Stock Vs. AbbVie

2024-09-11zacks.com

Pfizer (PFE) Upgraded to Buy: What Does It Mean for the Stock?

2024-09-11zacks.com

PFE or NVO: Which Is the Better Value Stock Right Now?

2024-09-11fool.com

2 Beaten-Down Stocks That Could Be Great Buys on the Dip

2024-09-10zacks.com

Why Pfizer (PFE) Outpaced the Stock Market Today
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data